On Nov. 16, 2020, BioNTech and Shanghai Fosun Pharmaceutica announced that the China National Medical Products Administration had approved the clinical trial in Mainland China for their mRNA vaccine candidate, BNT162b2. BioNTech through its partner Fosun Pharma was preparing to commence a Phase 2 clinical trial in Mainland China.